IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer.
Times cited: 20
Reprogramming tumor-infiltrating dendritic cells for CD103+ CD8+ mucosal T-cell differentiation and breast cancer rejection.
Cancer Immunology Research.
Times cited: 33